The Motley Fool··Jonathan PoncianoObesity Drug Stock Soars 60% on Phase 3 Progress Despite Fund's $4.7M Exit
Structure Therapeutics shares surge 60% as oral obesity drug aleniglipron advances toward Phase 3 trials with positive Phase 2 data, though HighVista Strategies trimmed its position.
GPCRPhase 3 trialsfund selling